What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. / Sæther, Sverre Georg; Schou, Morten; Kondziella, Daniel.
I: BMC Psychiatry, Bind 17, 161, 03.05.2017.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review
AU - Sæther, Sverre Georg
AU - Schou, Morten
AU - Kondziella, Daniel
PY - 2017/5/3
Y1 - 2017/5/3
N2 - Background: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes. Methods: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders. Results: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively. Conclusions: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.
AB - Background: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes. Methods: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders. Results: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively. Conclusions: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.
KW - Anti-neuronal antibodies
KW - Onconeural antibodies
KW - Paraneoplastic neuro-psychiatric syndromes
KW - Review
U2 - 10.1186/s12888-017-1325-z
DO - 10.1186/s12888-017-1325-z
M3 - Review
C2 - 28468645
AN - SCOPUS:85018740319
VL - 17
JO - B M C Psychiatry
JF - B M C Psychiatry
SN - 1471-244X
M1 - 161
ER -
ID: 190434789